B
Benjamin P. Brown
Researcher at Vanderbilt University
Publications - 19
Citations - 603
Benjamin P. Brown is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 5, co-authored 12 publications receiving 388 citations. Previous affiliations of Benjamin P. Brown include Baldwin Wallace University.
Papers
More filters
Journal ArticleDOI
Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury
Bradley T. Lang,Jared M. Cregg,Marc A. DePaul,Amanda Phuong Tran,Kui Xu,Scott M. Dyck,Kathryn M. Madalena,Benjamin P. Brown,Yi Lan Weng,Shuxin Li,Soheila Karimi-Abdolrezaee,Sarah A. Busch,Yingjie Shen,Jerry Silver +13 more
TL;DR: Systemic delivery of this peptide over weeks restored substantial serotonergic innervation to the spinal cord below the level of injury and facilitated functional recovery of both locomotor and urinary systems.
Journal ArticleDOI
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
Benjamin P. Brown,Yun-Kai Zhang,David Westover,Yingjun Yan,Huan Qiao,Vincent Huang,Zhenfang Du,Jarrod A. Smith,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Lyudmila Bazhenova,Alexa B. Schrock,Jens Meiler,Jens Meiler,Christine M. Lovly +15 more
TL;DR: The results fundamentally reframe the problem of targeted therapy resistance from one focused on the “drug–resistance mutation” pair to onefocused on the“activating mutation–drug–drug-resistance mutations” trio, which has broad implications across clinical oncology.
Journal ArticleDOI
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Ariella B. Hanker,Benjamin P. Brown,Jens Meiler,Arnaldo Marín,Harikrishna Sekar Jayanthan,Dan Ye,Chang-Ching Lin,Hiroaki Akamatsu,Kyungmin Lee,Sumanta Chatterjee,Dhivya R. Sudhan,Alberto Servetto,Monica Red Brewer,James P. Koch,Jonathan H. Sheehan,Jie He,Alshad S. Lalani,Carlos L. Arteaga +17 more
TL;DR: In this article, the role of HER3 mutations in HER2-mutant tumors was investigated using computational structural modeling with biochemical and cell biological analyses, and it was shown that the frequent HER3E928G kinase domain mutation enhances the affinity of HER2/HER3 and reduces binding of HER 2 to its inhibitor neratinib.
Journal ArticleDOI
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
Zhenfang Du,Benjamin P. Brown,Soyeon Kim,Donna C. Ferguson,Dean Pavlick,Gowtham Jayakumaran,Ryma Benayed,Jean-Nicolas Gallant,Yun-Kai Zhang,Yingjun Yan,Monica Red-Brewer,Siraj M. Ali,Alexa B. Schrock,Ahmet Zehir,Marc Ladanyi,Adam W. Smith,Jens Meiler,Christine M. Lovly +17 more
TL;DR: In this paper, the prevalence of ERBB family KDDs across multiple human cancers and evaluate the functional biochemistry of EGFR-KDD as it relates to pathogenesis and potential therapeutic intervention.
Journal ArticleDOI
In vivo and in vitro ketamine exposure exhibits a dose-dependent induction of activity-dependent neuroprotective protein in rat neurons.
Benjamin P. Brown,S.C. Kang,K. Gawelek,R.A. Zacharias,Sean R. Anderson,C.P. Turner,Jacqueline K. Morris +6 more
TL;DR: Data support the model that ADNP induction may be partially responsible for the efficacy of a low-dose ketamine pre-treatment in preventing ketamine-induced neuronal cell death.